-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 WaEUnHVtjUSmdqcj7GCTRIUffq/AHe6irsn/xwyv6I1Uw4rWeOsTHzV93pOBUavw
 EY1a8sFJQ+B8YCUfpeGuyg==

<SEC-DOCUMENT>0001130319-08-000242.txt : 20080318
<SEC-HEADER>0001130319-08-000242.hdr.sgml : 20080318
<ACCEPTANCE-DATETIME>20080318112346
ACCESSION NUMBER:		0001130319-08-000242
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20080318
FILED AS OF DATE:		20080318
DATE AS OF CHANGE:		20080318

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ONCOLYTICS BIOTECH INC
		CENTRAL INDEX KEY:			0001129928
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-31062
		FILM NUMBER:		08695317

	BUSINESS ADDRESS:	
		STREET 1:		1167 KENSINGTON CRES NW SUITE 210
		STREET 2:		CALGARY ALBERTA CANADA T2N 1X7
		CITY:			ALBERTA CANADA
		STATE:			A0
		ZIP:			00000
		BUSINESS PHONE:		4036707380

	MAIL ADDRESS:	
		STREET 1:		210 - 1167 KENSINGTON CRES NW
		CITY:			CALGARY
		STATE:			A0
		ZIP:			T2N 1X7
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>o39797e6vk.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
<TITLE>e6vk</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<HR size="4" noshade color="#000000" style="margin-top: -5px">
<HR size="1" noshade color="#000000" style="margin-top: -10px">

<P align="center" style="font-size: 14pt"><B>SECURITIES AND EXCHANGE COMMISSION<BR>
<DIV align="center" style="font-size: 12pt">Washington, D.C.
20549</DIV></B>


<P align="center" style="font-size: 18pt"><B>Form 6-K</B>

<P align="center" style="font-size: 10pt"><B>Report of Foreign Private Issuer</B>

<P align="center" style="font-size: 10pt"><B>Pursuant to Rule&nbsp;13a-16 or 15d-16<BR>
of the Securities Exchange Act of 1934</B>

<P align="center" style="font-size: 10pt">For the month of March 2008

<P align="center" style="font-size: 10pt">Commission File Number 000-31062

<CENTER>
<P align="center" style="font-size: 24pt"><B>Oncolytics Biotech Inc.</B>
<HR size="1" width="45%" noshade>
<DIV align="center" style="font-size: 10pt"><I>(Translation of registrant&#146;s name into
English)</I>
</DIV>
</CENTER>

<CENTER>
<P align="center" style="font-size: 10pt"><B>Suite&nbsp;210, 1167 Kensington Crescent NW<BR>
Calgary, Alberta, Canada T2N 1X7</B>
<HR size="1" width="45%" noshade>
<DIV align="center" style="font-size: 10pt"><I>(Address of principal executive offices)</I>
</DIV>
</CENTER>

<P style="font-size: 10pt">Indicate by check mark whether the registrant files or will file annual reports
under cover Form&nbsp;20-F or Form&nbsp;40-F.

<CENTER>
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="70%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="49%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="49%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">

<TD align="center" valign="top">Form&nbsp;20-F&nbsp;&nbsp;&nbsp;<FONT
face="wingdings">&#111;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Form&nbsp;40-F&nbsp;&nbsp;&nbsp;<FONT
face="wingdings">&#254;</FONT></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</CENTER>

<P style="font-size: 10pt">Indicate by check mark if the registrant is submitting the Form&nbsp;6-K in paper as
permitted by Regulation&nbsp;S-T Rule&nbsp;101(b)(1):&nbsp;&nbsp;&nbsp;<FONT
face="wingdings">&#111;</FONT>

<P style="font-size: 10pt"><B>Note: </B>Regulation&nbsp;S-T Rule&nbsp;101(b)(1) only permits the submission in paper of a
Form&nbsp;6-K if submitted solely to provide an attached annual report to security
holders.

<P style="font-size: 10pt">Indicate by check mark if the registrant is submitting the Form&nbsp;6-K in paper as
permitted by Regulation&nbsp;S-T Rule&nbsp;101(b)(7):&nbsp;&nbsp;&nbsp;<FONT
face="wingdings">&#111;</FONT>

<P style="font-size: 10pt"><B>Note: </B>Regulation&nbsp;S-T Rule&nbsp;101(b)(7) only permits the submission in paper of a
Form&nbsp;6-K if submitted to furnish a report or other document that the registrant
foreign private issuer must furnish and make public under the laws of the
jurisdiction in which the registrant is incorporated, domiciled or legally
organized (the registrant&#146;s &#147;home country&#148;), or under the rules of the home
country exchange on which the registrant&#146;s securities are traded, as long as
the report or other document is not a press release, is not required to be and
has not been distributed to the registrant&#146;s security holders, and, if
discussing a material event, has already been the subject of a Form&nbsp;6-K
submission or other Commission filing on EDGAR.

<P style="font-size: 10pt">Indicate by check mark whether by furnishing the information contained in this
Form, the registrant is also thereby furnishing the information to the
Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of
1934.

<CENTER>
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="70%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="49%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="49%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top">Yes&nbsp;&nbsp;&nbsp;<FONT
face="wingdings">&#111;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">No&nbsp;&nbsp;&nbsp;<FONT
face="wingdings">&#254;</FONT></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</CENTER>

<P style="font-size: 10pt">If &#147;Yes&#148; is marked, indicate below the file number assigned to the registrant
in connection with Rule&nbsp;12g3-2(b):&nbsp;&nbsp;&nbsp;82&nbsp;-&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>

<P>
<HR size="1" noshade color="#000000" style="margin-top: -2px">
<HR size="4" noshade color="#000000" style="margin-top: -10px">

<P style="font-size: 10pt">&nbsp;

</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<P align="center" style="font-size: 10pt"><B>SIGNATURES</B>

<P style="font-size: 10pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.

<P>
<CENTER>
<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR valign="bottom">
    <TD width="50%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="47%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>

<TD colspan="3" align="left" valign="top"><B>Oncolytics
Biotech Inc.</B><BR>
(Registrant)</TD>
</TR>
<TR><TD>&nbsp;</TD></TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR><TD>&nbsp;</TD></TR>
<TR valign="bottom">
    <TD valign="top">Date: March&nbsp;17, 2008</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Doug Ball
<HR size="1" noshade width="60%">
Doug Ball<BR>
Chief Financial Officer</TD>
</TR>
</TABLE>
</CENTER>

<P align="center" style="font-size: 10pt">&nbsp;

</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="65%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">

<TD rowspan="4" valign="top"><DIV style="margin-left:15px; text-indent:-15px"><IMG src="o39797o39797001.gif" alt="(ONCOLYTICS LOGO)"></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" nowrap>210, 1167 Kensington Crescent NW</TD>
</TR>
<TR valign="bottom">
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" nowrap>Calgary, Alberta</TD>
</TR>
<TR valign="bottom">
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" nowrap>Canada  T2N 1X7</TD>
</TR>
<TR valign="bottom">
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" nowrap>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center"><DIV style="font-size: 3pt; margin-top: 16pt; width: 100%; border-top: 1px solid #000000">&nbsp;</DIV></DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>FOR IMMEDIATE RELEASE</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Oncolytics Biotech Inc. Announces Publication of Research on Immune Response<BR>
to REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> during a Phase I Clinical Trial</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>CALGARY, AB, March&nbsp;17, 2008 </B>&#151; Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) (&#145;Oncolytics&#146;)
reported today that Dr.&nbsp;Kevin Harrington and his research group at The Institute of Cancer
Research, London, U.K. published the results of their work characterizing immune system responses
to administration of intravenous REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top"><SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> </SUP>in a Phase I clinical trial. The paper,
entitled &#147;Characterization of the Adaptive and Innate Immune Response to Intravenous Oncolytic
Reovirus (Dearing Type 3) during a Phase I Clinical Trial&#148; appears online in the March&nbsp;6, 2008
issue of <I>Gene Therapy.</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&#147;This important work further defines the relationship between viral therapy and human immune
response, and supports the development of our ongoing Phase II clinical trial program,&#148; said Dr.
Brad Thompson, President and CEO of Oncolytics.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The investigators conducted a detailed analysis of the immune effects of intravenous viral therapy
by collecting and analyzing immune response to the presence of the virus. The results suggest that
reovirus may stimulate the immune system to mount a dynamic immune response to the presence of
virus, increasing the potential to significantly enhance the efficacy of oncolytic virotherapy.
About a third of those patients also showed increases in NK (natural killer) cells following
therapy. The data support the development of interventions aimed at blunting the patient&#146;s immune
response, although preclinical data also suggest that maintaining a baseline level is necessary to
restrict systemic spread/toxicity of the virus.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>About Oncolytics Biotech Inc.</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses
as potential cancer therapeutics. Oncolytics&#146; clinical program includes a variety of Phase I/II
and Phase II human trials using REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>, its proprietary formulation of the human
reovirus, alone and in combination with radiation or chemotherapy. For further information about
Oncolytics, please visit <U>www.oncolyticsbiotech.com</U>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><I>This press release contains forward-looking statements, within the meaning of Section&nbsp;21E of
the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the
implication of the materials presented in &#147;Gene Therapy&#148; with respect to REOLYSIN</I><SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP><I>, the
Company&#146;s expectations related to the results of trials investigating delivery of
REOLYSIN</I><SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP><I>, and the Company&#146;s belief as to the potential of REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> as a
cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the
Company&#146;s actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties
include, among others, the availability of funds and resources to pursue research and development
projects, the efficacy of REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> as a cancer treatment, the success and timely
completion of clinical studies and trials, the Company&#146;s ability to successfully commercialize
REOLYSIN</I><SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP><I>, uncertainties related to the research and development of pharmaceuticals</I>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>and uncertainties related to the regulatory process. Investors should consult the Company&#146;s quarterly
and annual filings with the Canadian and U.S. securities commissions for additional information on
risks and uncertainties relating to the forward-looking statements. Investors are cautioned against
placing undue reliance on forward-looking statements. The Company does not undertake to update
these forward-looking statements.</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>FOR FURTHER INFORMATION PLEASE CONTACT:</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="31%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="31%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="31%">&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="left" valign="top">Oncolytics Biotech Inc. <BR>
Cathy Ward <BR>
210, 1167 Kensington Cr NW <BR>
Calgary, Alberta T2N 1X7<BR>
Tel: 403.670.7377<BR>
Fax: 403.283.0858<BR>
<u>cathy.ward@oncolytics.ca</U>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">The Equicom Group<BR>
Nick Hurst<BR>
325, 300 5<SUP style="font-size: 85%; vertical-align: text-top">th</SUP> Ave. SW<BR>
Calgary, Alberta T2P 3C4<BR>
Tel: 403.538.4845<BR>
Fax: 403.237.6916<BR>
<u>nhurst@equicomgroup.com</U>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">The Investor Relations Group<BR>
Erika Moran<BR>
11 Stone St, 3rd Floor<BR>
New York, NY 10004<BR>
Tel: 212.825.3210<BR>
Fax: 212.825.3229<BR>
<u>emoran@investorrelationsgroup.com</U></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>o39797o39797001.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 o39797o39797001.gif
M1TE&.#EA&P$[`/<``/W]_?[^_OO[^WAX>/S\_/KZ^O'Q\7EY>?CX^/3T]*2D
MI/;V]O?W]_GY^>GIZ7=W=U5553HZ.JZNKN7EY?7U]>OKZZJJJ@8&!M?7UQX>
M'M/3T]_?WP<'!PL+"PP,#.[N[AD9&3$Q,>SL[&-C8^3DY*.CH^'AX=W=W7)R
M<G1T=+BXN`("`@D)"8V-C104%-K:VMS<W//S\^?GYV5E9<?'QXB(B,G)R=O;
MVZ>GI[N[NZBHJ!86%AP<'.#@X/+R\DE)2<W-S;*RLAT='8R,C,+"P@,#`]C8
MV!(2$A,3$Q@8&#(R,BTM+3T]/>CHZ.+BXNWM[0$!`1\?'\/#PPT-#7!P<-+2
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M*Z:FIM#0T`0$!)"0D+&QL9J:FF9F9E145%965DY.3E)24I&1D=[>WJ^OKZ*B
MHB(B(C\_/]34U`@(")*2DL#`P)F9F8"`@,O+RTI*2B`@('Q\?)R<G+FYN4Q,
M3"<G)SP\/"$A(8Z.CHF)B6AH:$5%12DI*6QL;$M+2Y>7EUM;6[JZNI:6EB\O
M+YZ>GFEI:<'!P3@X.%E965Y>7D!`0",C(\7%Q8&!@1<7%Q`0$#`P,`\/#SL[
M.V]O;RHJ*FMK:V!@8*6EI1H:&BXN+I65E=75U:&AH6UM;7U]?9.3DVIJ:B@H
M*%A86&)B8F=G9Q$1$5-34[^_OWM[>V%A834U-5]?7XN+BX>'AU!04*VMK0``
M`/___P```````````````"'Y!```````+``````;`3L```C_`/<)'$BPH,&#
M"!,J7,BPH<.'$"-*G$BQHL6+&`\&\+&!B)X[;][4>%7KRP<!&5.J7,FRI<N7
M,`D2J*!&&*@B^G+JW*E/2+<@)PK$'$JTJ-&C2/>)&0%J%,^G/%=DR,6F0=*K
M6+-J19J`U@^H^D:1`4.-&C==%\`&>S-AJ]NW<.,N7&#'UY2=';2M&F;!DY<;
M&S;`^`1'`KEVC;+LY+`I5!.YD"-+-MID&,\IJKCT`,`0P`<+Q!3K+'((QN33
MJ%-3)+)G)YDS)"@FL%(&+QJAJG/KUAU@D>B<B,1PK@B@PIV[.3O$V<V\.60"
MNUCH_&-CI9,M''1"$N&\NW>D,;AT_\CI8<2&`"R=W-J1L]*9#]_CRV\9ZC<5
M`R\IR-&YK<W\_P!2A$8&.K%B54RE>*"3'B@%Z."#!R4`@G8-QD0`(3HA\0J$
M'$*X`!TZS<'`46]4DA,L\'6HXGRNC*=/"-P=54$J.AUSX(HX-H>`$CGMH,-5
M-%234Q:?Y&BD;@"$HU,*6`'`C$ZH#'?DE))9(DE.>P"1U0(NZ&0:E6#*I8-.
M+51X%2%IZ7,&`F&VN94`,^2TP@E;37"E/G@8X>:>5W'"HSY,H*>5DSH5PN>A
M1F&RC3Y0V/'6!$L*BNBD+E&14Q)BO$6`(SG%L@"EH++TE3Y*^`"7(#DM\0)"
M"U@PP*O"L/]Y$`,'O+J&0PP8D8P6IW0QAC(SS/$&#4](B1`#:]B#P@S*_.I.
M"G%4,>)"!<CQZC"2*A3#`Z]"LHA"!>3PZ@!V$#`0`Y.,J^ZZZR9RT`WC;M"0
M`"?@\,`SOM)Q"@J"I%&!N0B)D,8`,ZR22S18A`$.%36H\=A``$21TR,`NX6A
M/CRH@%`@-.8TBQ8R'%2!3KLL!``)O$A2AH)("+$'#PH6X<@Q#QM$0"NF($/)
M!2L<H<LO462SPBS&7/)*#]D6E``3.7%@9D(%N*&@/F0L\[1`#3!"H#YE="*I
M"&F"]10?&AMTL3ZE+!1($&,T@X0^4V1`210QDR&)*"*W\`</^A3_D8$Q2QC#
M0UI]9("'+0U2`$5.#\1%1!_Z\$$+0@Y`P!,*GQ8T,N,+23&J/END$$H.7O22
MC!EA(*-"Q05)$0OD%SR"C@+0$&9M,3KY(D5""42@T]4((7"/3B#L;A`.XN3$
M`R[9(N#&`=!#?\@1J:(0/?1QU$R0!3I)D%``/:22'13>F&&+&KC`844*TC"!
M0^8$Q7",3EA<HT857R221@WG7-*!(S805!-T$HJX:*!+^H`$Y2RG#PYD1Q^1
M@)]`**"3Q@4/!SJI0Y$DP@8AY`0$>D)((4R4$T\8:R"]^QU$XD!"?7@"-_LH
MP)ARLHDO+<0(?SH$?AK"O9QX3R,22$)._X(1A!,R1`$Z&0.X;K0/$^@$#G$Y
M@0?5M,"<*.$6.LD$!0C"@`HF)`C4TT<NZ"01`DP1&SA0"`#TH!-0R")"OLL)
M\!(B`"[H9`>8&(@A7`0*)R0-(1@(04Y&L$.&]%`?/S2(%Y:@DR\8D2%/RDD=
MYG@0)^;$>&\A`25R,H<JXBD&6G#1%@!Q+B\>Y`E@T$EU)E((G40@!B9;ATZH
M`$<50H0`.>"#3DSQ!#OFA!UM<4@@!UG(A<P0D0@)@TZ<09$KI$`GV)@!*9:Q
M`0,\4B"6U$<\XM(*B>E#"Y[4QA4<\(T'SN`&`BF`*0VRC"GJPU02"4`7<L<Z
MA+!#)Q"HI1S+J/\`3NDC"71@CS[J@0&(#%,?A'0(&WTX*^1LPPL5N8(SMH!`
M%@BA&6#8PBUPL`81L,X2.G$47,HAT`-X<@G<(4$[LA@;`JRS(%:8VB@HJ1`"
M,"TGJ_BC08BADV+H4Q\T_5X.)K238C@@(@=-*`^[=Q`1Z$0(-J3(!W30!6_R
M!`1TL,*T]A$#G2`B+M;(#@=:X,DR5$`@`"!&FK@!"`!(1Q\6-$@AA)@3"3XD
M`(?0"3!DI9`XY405/PVJ0C3A3WV$88M(%21"BZF00R:2(`E(DPNJD)(`&&`#
MG4@!$_8`N9QX(V3[```"MW#-I`3A@YWPY"]`NX\$M$$GJS!`:^"*$!G_X$$G
ME)V((G0RCJ@BI`XZ44=@*R(`W%UR(DEE;$(<JQ$LY`0*%FA)``I@"0FD"0H_
M$L@6K`A/MV!1'ZKR)"6".9`6(!`9C>`<0@SA%'U$`V\2`4`<5_",A7A!)QG(
MP7`I(@#GYH0&R%6L4AERS,<2I!3)TX<+@%#:BWQ#)XP8"$\QMBJW$."V@.IN
M02J7DPR0<2`Q$(9`WQI7@U1@`,AA0@F:\+0`,&`#5T`(#6*1DR,HP`%)<S$T
M;GH$<_`5LG'4!PPETE^=`%@BR54H4P_2`"L0]1>L^,*0!8(`3CSACS)8Q"!D
M0`$CQD`*H""/)P9""NFL@`UO"81.W*'3?7"8_VH5)@@%#,&3$AND`'$0J&$'
M$`0@R"(1BJ`%%6+Q`-86Q`O(D`X+(,`*1<!`!IS0@`ZH0-0,6(%W06Y#"X;`
MZ4X/H0;R4DB1_QM@8CJ$N0AI0"'&D9,^T&,`"@""!C1`A&3,X1%=R.VYX*$/
M743B'(+(AZPUX`<%/.-M^KC`,&[T`D;J8PQM-DH`]I.3Z&Z,@5EXXT&"T$*3
M+J0!+0#&UG@"A6R4@1HE4`@1(A$%G$`E&\UHPQ,4DD*QZ600"Q'`(W3BAXD8
M0;$Z/'6AOHT&,`0C;#N9PA[`8(AL;8`;2WC'"L3&@C*,X,/I5*8^5A"CK'Q@
M&CE9AZX-@@!KE$`!$O^`Y4$(H(F3ER#."@D`!4Z`!G/<01X'J`$OM"R"!D0[
MG:WH!29J4*L!7(,<%OC$!WZ^#P)XXN0*B+K4I5X"!BTD`$`X>3AB+)$$J$$!
M)1A$/1-B":B?E2$(,$$M2L"*71S@#9@HA1<F@(`_"D`$HE@$(VI@AD/,8`8H
MN`,.K%$!X(6"3(*%B0XZNZ90.5XE+XAC'C*%E07\21\!?+SF+R*`..BD!DTZ
M6S3&OOG2/\0'V#@1$:ZB@4WDA`^K-[WL)8()O3*=)07(A$Y^P,39^WXA%$#%
MDGX\%#<@)QCS[HP`EG_[@02``,U'ZP(6D/A]!&#Y`B``]AML?>UCO_K61P#_
M!::,D.=G"_HL,3]#GB^EYT,$``R@`.DA(@:Z>D`8X"<N&Q#X#E(TQ`!M(`EG
M``F(T`TXD'P*L0&1`$4+00`VT`8H,`F"D`(/$`3$9Q`GT`8',`-_H`X#\`"!
ML!`D@`I=`#T#<`>]9Q`!\`)R,`?R(`AGX`S<)PI8T`,#(06JX"XKL6XVN!!`
M``'28`/F(@JJ4`[KMP:TH`63,`DHD`/1AQ!6@&QHDW\3H0E$I0]N8%>4@PJ;
M\`(D<`.YD`%JP!":,`O^MQ!50`9A0`.`8``],`]%0`@TQ0`3P`F\H`]I0`(D
M$%2)<`1:H(<D(`-,IP$_@`?Q4`$^X`2AIA"=H`^*_\``D$@*^H`&+)$,+-!O
M"V$!/%`&8K@/C=@+5V<#U9`)-'`%5W`#1W41=_!6^A`'%Y@2!5`+.L$!I_`0
ME=,!F]`(2D`&IX!Q".$'?)`.D*0/T$`0)@`+TY`B"^$*^J`!#J$!2)`$>9`'
MOF`)#&$&1Y!N$,$&^F`,TY@'?$.)*V$*'7`K"V$'U6`+7.`!+3`F^J40#1`!
M6;!**F$`<Z`3'C``+@$`AJ!G=("`#%$Y8"`"!F``M?`+J,`0P"B,"T$#1_``
M"3`0O3`+*/"*!L&,SM@0T.@&!>D#W+</;!`%RF"1",&-FC!]"V!'XJ@2Y&B.
M"F$'("`(`@`'24`@[Y@0`/_`"T4P!"GX/1^0"!&9$`1P``^D#Y=`CQ@1`":`
M!45Y`!W7$(#@!C_P#68P`/-P`/BV$%_P`T&P?AAP#*>`"&Z0`M,@!SUY$'YP
M"3W($!N`#Q!`!69`!=U`7@E1!8A`!V:`#KM0`^17$+A0!^@D$&GP"%JR$FGP
M`S"'$(J0"FFT#TZ@!9=0F`NQ#"@`#BDP"0>``WTY$%=P#2%PDPAA`.:E$Y3`
M!4;PD6H4"+:02LF!`DOW?A70"C<``R;@`%IX$`7@!+=Y$!0P`1@@!C?P`:@I
M$`S0`]4G`)QP`C```S=P`V=)$-,E`U^``28`"$R7=C"T`$Y`DA2AG9O)11,0
ME/OKX(;<Z7R]*09&,`$Q\'/%803BJ1"F<(7ZT`BOH(P1P0`J,`8[<0$UL)N_
M]Y\2\072P!,N,``V8)WKMP`:8`A6Q2A_X)(`&J$600&,0%?XJ`V9X`HFX',%
MT0`3``<HT`AZIA-6H#T2>J(4X0,M`%Q0,0H\$`%_\`?```L(MQ.ZP!8HFJ,7
M40`FP`CPX`T39V]1(01U,`2X\)TZFJ0.@0"R@`A=``*+8V](\`,'D`.(I:18
MBA$S,0AIH`)>^J4J0`,3\)Q9BJ(`<*9HFJ9JNJ9LVJ9N^J9P&J=R.J=T6J=V
/>J=XFJ=ZNJ=\RJ8!`0`[
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
